Quantcast
Last updated on April 18, 2014 at 10:36 EDT

Latest Biological therapy for inflammatory bowel disease Stories

2013-11-26 08:27:02

- New results show BL-7040 to reduce pro-inflammatory cytokine levels and improve colon histology in IBD patients - JERUSALEM, Nov. 26, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX)(TASE:BLRX), a biopharmaceutical development company, announced today additional Phase 2a results showing significant improvement of disease measurements in biopsies taken from inflammatory bowel disease (IBD) patients treated with BL-7040, an orally available drug for treating IBD. The histological and...

2013-08-22 12:52:15

Vedolizumab, a new intravenous antibody medication, has shown positive results for treating both Crohn's disease and ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine. The findings, published in two papers, will appear in the August 22 issue of the New England Journal of Medicine (NEJM). William Sandborn, MD, principal investigator of the Crohn's disease study, said the results offer new hope to the more than one million Americans...

2011-11-07 01:00:00

BRUSSELS and CHICAGO, Nov. 7, 2011 /PRNewswire/ -- UCB today announced findings from a post-hoc analysis suggesting that disease activity response rates to Cimzia(® )(certolizumab pegol) plus methotrexate (MTX) as early as Week 12 helped predict the effect on structural joint damage in patients with moderate to severe rheumatoid arthritis (RA) at one year. Comparable responses were found by both RAPID3 (Routine Assessment of Patient Index Data 3) and EULAR (European...

2011-08-23 21:35:09

Inflammatory bowel disease (IBD), which affects more than 1 million patients in North America, results from an uncontrolled immune response triggered by environmental factors, such as bacteria, in people genetically predisposed to the disorder. Ulcerative colitis, or inflammation of the lining of the colon, is one such condition. The aberrant immune response found in IBD is prompted by different cytokines — small signaling proteins secreted by various cells, including immune cells...

2011-05-16 09:00:00

BRUSSELS, May 16, 2011 /PRNewswire/ -- The ACR hybrid score, a new measure of response to RA treatment recently developed by the American College of Rheumatology, demonstrated improved sensitivity compared to traditional ACR responses, according to recently published results in Arthritis Care & Research. Traditional ACR20/50/70 and DAS28 scores were compared to the ACR hybrid score in a post-hoc analysis of the RAPID 1 study, the first clinical trial data to be analyzed using the ACR...

2011-05-10 09:00:00

BRUSSELS, May 10, 2011 /PRNewswire/ -- UCB announced results from a post hoc analysis of the RAPID 2 study, published in the Annals of Rheumatic Diseases, which showed Cimzia®, the only approved PEGylated anti-TNF, plus methotrexate (MTX) provided rapid relief from a broad range of symptoms associated with the burden of moderate to severe active rheumatoid arthritis (RA). Those adult patients treated with Cimzia® that achieved early responses were found...

2011-05-10 09:00:00

BRUSSELS, May 10, 2011 /PRNewswire/ -- UCB announced today results from a post hoc analysis of the RAPID 1 study published in the Journal of Rheumatology. The results suggest moderate to severe rheumatoid arthritis (RA) patients treated with Cimzia® (certolizumab pegol), the only approved PEGylated anti-TNF, together with methotrexate (MTX), achieved a rapid response associated with improved long-term outcomes one year after treatment began. "These results are consistent...

2010-08-05 16:18:43

Biological agents may play an important role in maintaining remission in Crohn's disease, according to two new studies in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association (AGA) Institute. "Post-surgical recurrence of Crohn's disease occurs very frequently. Unfortunately, none of the traditional drugs used to treat the naturally occurring disease has really shown a clear-cut benefit in this situation," said Dario R. Sorrentino, MD,...

2010-04-19 10:18:32

Cystic fibrosis (CF) is the most common life-threatening autosomal recessive disease in Caucasian children; it has an incidence of 1 case in every 2500 children born alive. CF involves an anomalous function of the exocrine glands, caused by a mutation of a gene (cystic fibrosis transmembrane conductance regulator, CFTR) located on chromosome 7, which codes for a protein involved in ion transport through the cell membrane. Pulmonary complications are the most common causes of mortality, but...

2005-12-07 17:57:54

NEW YORK (Reuters Health) - Treatment of moderate-to-severe active ulcerative colitis, a severe inflammatory disease of the colon, with the drug infliximab is associated with sustained clinical responses and intestinal healing, according to results of two studies reported in The New England Journal of Medicine. Infliximab, an antibody that binds to an inflammatory protein, is effective for treatment of Crohn's disease, Dr. William J. Sandborn, from Mayo Clinic in Rochester, Minnesota,...